Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Wockhardt Limited
WOCKPHARMA | NSE
1,892.90
INR-28.00
-1.46%
WOCKPHARMA | NSE
Loading StockChartView...
About Wockhardt Limited
Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
Earnings date
31/03/2024
As of date
08/06/2026
Close
1,892.90
Open
1,900.00
High
1,964.00
Low
1,856.00
Wockhardt Limited a pharmaceutical and biotechnology company manufactures and markets active pharmaceutical ingredients formulations bio-similars and vaccines in India the United States the United Kingdom Ireland Mexico Russia and internationally. It develops various molecules primarily in the areas of infectious diseases such as WCK 5222 WCK 4282 WCK 4873 WCK 771 and WCK 2349 and WCK 6777 molecules. The company's biopharmaceutical products include Glaritus an insulin analog; Wosulin an r-DNA insulin; Wepox a recombinant erythropoietin that is used in the treatment of anemia caused by cancer and chronic renal failure; and Biovac-B a hepatitis B vaccine. It also provides contract manufacturing services for sterile injectables lyophilization and other dosage forms; and research services. The company was founded in 1967 and is headquartered in Mumbai India. Wockhardt Limited is a subsidiary of Themisto Trustee Company Private Limited.
View LessWOCKPHARMA | NSE
Risk
79.2
Sharpe
0.64
Luna's Score
49/100
Recommendation
Hold
Luna says (WOCKPHARMA | NSE)
What's Working
Strong Revenue Growth (> 10%)
What's not Working
Price Below SMA10D
High Short-term Volatility
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
108.2%1 month
79.2%3 months
64.8%6 months
51.0%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
4.82
Debt to equity
0.70
Debt to assets
0.31
Ent. to EBITDA
90.65
Ent. to rev.
6.26
PEG
-
Other Fundamentals
EBITDA
2.08B
MarketCap
290.41B
MarketCap(USD)
3.03B
Div. yield
-
Op. margin
5.14
Erngs. growth
840.60
Rev. growth
14.80
Ret. on equity
-12.89
Short ratio
-
Short perc.
-
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
851.30
Range1M
917.30
Range3M
1.34K
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.85
Price X volume
5.37B
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 90.65 | 24.85 | Expensive |
| Ent. to Revenue | 6.26 | 11.40 | Cheaper |
| PE Ratio | - | 51.36 | - |
| Price to Book | 4.82 | 6.83 | Cheaper |
| Dividend Yield | - | 0.52 | - |
| Std. Deviation (3M) | 64.76 | 42.17 | Riskier |
| Debt to Equity | 0.70 | 0.35 | Expensive |
| Debt to Assets | 0.31 | 0.17 | Expensive |
| Market Cap | 290.41B | 290.82B | Par |
